Hudson Bay Capital Management LP Invests $37.44 Million in argenex SE $ARGX

Hudson Bay Capital Management LP purchased a new stake in argenex SE (NASDAQ:ARGX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 67,923 shares of the company’s stock, valued at approximately $37,441,000.

Several other large investors have also recently bought and sold shares of ARGX. WPG Advisers LLC purchased a new position in shares of argenex in the 1st quarter valued at about $37,000. Brooklyn Investment Group grew its position in argenex by 102.7% during the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock worth $44,000 after buying an additional 38 shares during the period. MAI Capital Management increased its holdings in argenex by 866.7% in the second quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after buying an additional 78 shares in the last quarter. Banque Transatlantique SA acquired a new stake in shares of argenex during the 1st quarter valued at approximately $62,000. Finally, Geneos Wealth Management Inc. boosted its stake in shares of argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after acquiring an additional 99 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ARGX shares. Jefferies Financial Group set a $818.00 price objective on argenex and gave the company a “buy” rating in a research note on Tuesday, August 26th. Wells Fargo & Company upped their target price on argenex from $1,095.00 to $1,316.00 and gave the company an “overweight” rating in a report on Thursday. Stifel Nicolaus lifted their price target on argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a research note on Thursday. Wolfe Research reiterated a “peer perform” rating on shares of argenex in a research report on Monday, November 24th. Finally, Wall Street Zen raised shares of argenex from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, argenex presently has an average rating of “Moderate Buy” and a consensus target price of $968.83.

argenex Price Performance

NASDAQ:ARGX opened at $877.94 on Friday. The firm has a market cap of $54.05 billion, a PE ratio of 37.70, a P/E/G ratio of 0.89 and a beta of 0.37. The firm has a 50 day simple moving average of $863.28 and a 200-day simple moving average of $716.27. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62.

argenex (NASDAQ:ARGX) last announced its earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. As a group, sell-side analysts expect that argenex SE will post 3.13 earnings per share for the current fiscal year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.